What is healthtech and why does it attract so much venture capital?

Helthtech refers to the sector that combines healthcare products and services with advanced technologies to improve medical care, diagnostics, treatment, and operational efficiency. 

The field encompasses everything from mobile applications and wearable devices to sophisticated artificial intelligence systems for diagnostics and clinical big data platforms for predictive analytics.. 

The scale of this transformation is reflected in market data. According to Fortune Business Insights, the global digital health market was valued at $427.24 billion in 2025 and is expected to reach $491.62 billion in 2026. 

This growth is explained by technology’s ability to enhance operational efficiency, improve clinical interoperability, personalize treatments through predictive algorithms, support earlier diagnoses, and cut unnecessary patient travel through telemedicine. 

Therefore, investing in healthtech is betting on a more equitable and financially sustainable model. In fact, there are already more than 140 healthtech "unicorns" worldwide, startups valued at $1 billion or more pre-IPO, according to HolonIQ's latest unicorn report.  

While related, these concepts are not interchangeable: 

• Healthtech encompasses digital health solutions and software applications, including telemedicine platforms, AI-powered diagnostics, and healthcare data systems.

• Medtech focuses on physical medical devices such as ventilators, imaging equipment, and surgical technologies.

• Biotech centers on molecular innovation, including pharmaceuticals, biological therapies, and gene-based treatments. 
• eHealth is a broader umbrella term covering any application of technology within healthcare. Healthtech generally represents its most innovative and digitally driven segment. 

Healthtech spans a wide range of technologies designed to improve healthcare delivery, disease prevention, diagnosis, treatment, and overall well-being.

Among the categories attracting the strongest investor interest are:

• • Telemedicine and remote care. Video consultations, digital communication platforms, and remote healthcare services eliminate geographical barriers, particularly for rural populations and patients with limited mobility.  
  • AI‑driven diagnostics and clinical big data. Algorithms capable of analyzing medical images, predicting cardiovascular conditions, and identifying patterns across large-scale patient datasets improve diagnostic accuracy while helping healthcare systems allocate resources more efficiently. 
  • Digital mental health and emotional well-being.  This category includes online therapy services, virtual psychological support platforms, and AI-powered emotional monitoring tools that identify patterns associated with anxiety, stress, or mental health challenges. 
  • Clinical software, interoperability and hospital management. Solutions that connect healthcare institutions and unify data streams reduce duplication, improve data accessibility, and enhance care coordination. 
  • Digital therapeutics (DTx) and personalized medicine. Digital therapeutics are evidence-based treatments delivered through software. Examples include diabetes management applications and cognitive therapies for individuals with ADHD. 

For specialized venture capital investors, these solutions offer an attractive combination of persistent demand, technological scalability, and regulatory barriers that create defensible competitive advantages. 

Several factors have converged to make healthtech particularly attractive to investors: strategic resilience, a maturing regulatory framework, and the sector’s ability to deliver both financial returns and societal value—an acceleration intensified by the COVID‑19 pandemic.

The pandemic acted as a structural accelerator, driving healthcare technology adoption at a pace that might otherwise have taken decades. Both patients and healthcare professionals embraced digital healthcare solutions at unprecedented speed.  

In Spain, investment in healthcare technologies within the National Health System increased by 16.7% between 2020 and 2021. 

Likewise, the European regulatory framework has also matured. The Data Governance Act is a European regulation  that facilitates the secure exchange of health data for innovation. It facilitates the training of algorithms with robust datasets.

For its part, the European Union's Artificial Intelligence Regulation is the world's first legal standard on AI. It establishes clear requirements for high-risk systems in medicine, reducing legal uncertainty.

Healthtech investors typically evaluate opportunities through three key lenses: 

1. Scalability 
2. Recurring revenue potential. 
3. Hybrid expertise within the founding team. 

Put differently, investors look for companies that successfully combine clinical insight, technological capability, and regulatory rigor. 

Early clinical validation through pilots, trials, and real-world testing is particularly important. Projects must also demonstrate measurable outcomes, such as improved population health, reduced healthcare costs, or enhanced clinical efficiency. 

For investors, healthtech offers a compelling combination of growth potential and resilience.

Unlike sectors such as fintech or e-commerce, healthcare demand tends to be relatively inelastic. People require healthcare services regardless of economic cycles.

This characteristic contributes to more stable valuations and multiples than many purely digital technology sectors. 

In addition, regulatory barriers, including clinical validation requirements and medical certifications, create a significant competitive moat. Once a company successfully clears these barriers, it becomes more difficult for competitors to replicate its position.

As a result, returns combine strong financial ROI with measurable social impact, attracting both traditional funds and impact investors focused on ESG aligned outcomes.

Investors seek founder profiles with clear competitive advantages. The winning formula lies in the combination explained below.

Founding teams are one of the most decisive factors in raising capital, especially in the early stages. In healthtech, investors favor teams with sector experience, growth mindset, and strong scientific‑technical capabilities. 

Teams that bring together physicians, engineers, and regulatory specialists not only gain faster access to capital but also build greater credibility. 

Clinical expertise reveals real problems within the health system, while technical vision translates those challenges into scalable solutions.

Spain’s healthtech ecosystem demonstrates increasing maturity through a growing diversity of startups securing international capital and validating their business models. 

Success cases such as Idoven (AI‑powered cardiac diagnostics) and Psious (virtual‑reality mental‑health therapy) illustrate the sector’s viability. Another reference is Atrys Health, showing how telemedicine, genetics, and AI can build more equitable health systems.

Healthtech startups attract venture capital because they combine scientific rigor, rising demand, and an ecosystem capable of converting innovation into sustainable economic value.

Turning science into business requires an ecosystem that connects research, clinical practice, and market deployment— ensuring  agile technology transfer from the lab to the market..

Within this environment, Bolboreta Investiga, helps reduce uncertainty and accelerate innovation transfer in healthtech, driving the tangible impact of deep science projects.. 

If you are ready toI take the first step from the idea to the market, do not hesitate to get in touch and tell us about your project.